Activist investor Nelson Peltz’s Trian Fund Management is advocating for further business separations at Solventum following the company’s recent $4.1bn sale of its filtration unit, according to a report by the Wall Street Journal citing unnamed sources familiar with the matter.
On Tuesday, contract drug manufacturer Thermo Fisher Scientific announced its acquisition of Solventum’s purification and filtration business with Trian describing the deal in a statement as “an important first step in the company’s value creation journey,” while emphasising that Solventum has substantial opportunities for cost reduction.
Trian, which holds around 5% of Solventum’s shares and is its largest active shareholder, believes that a more streamlined business “should be able to deliver faster organic growth and higher margins as a focused, standalone company.”
Earlier this year, in a letter to Solventum shareholders, Trian urged the company to simplify its business structure to enhance performance within its core medical surgery segment.
The hedge fund has argued that divestitures could accelerate Solventum’s debt reduction efforts while enabling it to allocate resources toward dividends, share buybacks, and mergers and acquisitions.
A spokesperson for Solventum stated, “We are excited about the rapid progress we are making to transform Solventum and look forward to continuing to drive value for shareholders.”
